Plain-English translation of NCT05127148 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is collecting real-world evidence on how well a pediatric-style chemotherapy treatment works for teenagers and young adults (ages 18–40) with Philadelphia-negative acute lymphoblastic leukemia (a type of blood cancer). Researchers want to understand whether using children's treatment protocols—which tend to be more aggressive—helps these younger adult patients survive longer and what side effects they experience. The study will also track how well patients respond to treatment at different time points and whether they benefit from additional procedures like bone marrow transplantation.
Teenagers and young adults with this type of leukemia have been traditionally treated with adult protocols, but recent evidence suggests that more intensive, pediatric-style approaches may improve survival in this age group. This trial aims to gather real-world data from actual practice in Argentina to confirm whether this approach is truly better and safer than standard adult treatment.
You likely qualify if…
You likely don't qualify if…
Participants will receive intensive chemotherapy given in phases over several months, starting with a pre-treatment steroid phase, followed by induction (the main attack on cancer cells), consolidation (strengthening the response), re-intensification, and then either ongoing maintenance therapy or a bone marrow transplant, depending on their risk category and how well they respond. Throughout treatment, you'll have frequent blood tests and bone marrow checks to monitor your response and watch for side effects. The research team will track your survival, quality of life, and any serious side effects over time.
AI-generated summary from trial data · Aug 8, 2026 · Not medical advice
Argentina
Sponsor
Grupo Argentino de Tratamiento de la Leucemia Aguda
Enrollment target
~100 participants
Started
March 2021
Primary completion
March 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 40 Years
Last updated on clinicaltrials.gov in January 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Luciana Ferrari, Dr.
Grupo Argentino de Tratamiento de la Leucemia Aguda
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.